Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tg1-90B
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Parenteral
01
Overview
Tg1-90B is a novel small molecule radioligand developed for the detection and imaging of alpha-synuclein (α-syn) aggregates, which are the pathological hallmark of synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). It specifically targets "Site 2" on α-syn fibrils. Research conducted at the University of Pennsylvania has demonstrated that Tg1-90B acts as a "pan-α-syn" tracer, showing specific binding to α-syn inclusions in post-mortem brain tissue across PD, DLB, and MSA. This broad reactivity distinguishes it from other site-specific ligands that may only recognize aggregates in specific disease states. Tg1-90B is intended to serve as a diagnostic tool to improve the accuracy of diagnosis, monitor disease progression, and support the development of α-syn-targeting therapies.
- Other names
- [3H]Tg1-90B
02
Targets
Amyloid fibrilsaggregated α-syn (Alpha-synuclein (α-syn))Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on Tg1-90B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tg1-90B.